AtriCure is a medical instruments & supplies business based in the US. AtriCure shares (ATRC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.16 – an increase of 7.8% over the previous week. AtriCure employs 1,200 staff and has a trailing 12-month revenue of around $430 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $29.16 |
|---|---|
| 52-week range | $18.94 - $43.00 |
| 50-day moving average | $25.85 |
| 200-day moving average | $27.16 |
| Wall St. target price | $41.13 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.86 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $28.61 from 2024-10-15
| 1 week (2024-10-10) | 5.77% |
|---|---|
| 1 month (2024-09-17) | 1.92% |
| 3 months (2024-07-17) | 14.12% |
| 6 months (2024-04-17) | 22.00% |
| 1 year (2023-10-17) | -19.54% |
|---|---|
| 2 years (2022-10-17) | -20.90% |
| 3 years (2021-10-13) | N/A |
| 5 years (2019-10-17) | 4.76% |
| Revenue TTM | $430 million |
|---|---|
| Gross profit TTM | $245.9 million |
| Return on assets TTM | -3.65% |
| Return on equity TTM | -8.68% |
| Profit margin | -9.33% |
| Book value | $9.49 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting AtriCure to pay a dividend over the next 12 months.
Over the last 12 months, AtriCure's shares have ranged in value from as little as $18.94 up to $42.9999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AtriCure's is 1.438. This would suggest that AtriCure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.